News NICE recommends Celgene pancreatic cancer drug Abraxane finally gets NHS funding following price cut.
News UK and US spearhead search for drugs targeting RAS mutations Cancer Research UK and its Cancer Research Technology Pioneer Fund have joined with the US National Cancer Institute (NCI) to test new molecules targeting RAS mutations.
News NICE rejects Shire pancreatic cancer drug Onivyde not eligible for Cancer Drugs Fund, says NICE.
News Shire's Onivyde pancreatic cancer drug approved in EU Drug approved in metastatic adenocarcinoma of the pancreas.
News FDA experts lukewarm on AZ's anticoagulant antidote Andexxa AstraZeneca is facing some pushback as it tries to upgrade anticoagulant antidote drug Andexaa to full approval in the US
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
